Furthermore, it remains to be elucidated, how frequently the loss of SATB2 occurs in comparison to the loss of CDX2 and whether SATB2 can identify distinct prognostic groups within these colorectal cancer subsets. This evidence concerns the gene SATB2 and colorectal cancer.